La chaîne d'options affiche les données clés des options sur actions de Maximus à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Maximus..

Maximus (NYSE:MMS) Stock, Chaîne d'Options

Maximus

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Maximus Inc

IndexIQ Active ETF Trust IQ MacKay Multi-Sector Income ETF

MEGMILK SNOW BRAND CO LTD by MEGMILK SNOW BRAND CO LTD.

Megmilk Snow Brand Co Ltd

First Trust Multi-Manager Small Cap Opportunities ETF

New York Life Investments Active ETF Trust NYLI MacKay Muni Short Duration ETF

MACARTHUR MINERALS LTD by Macarthur Minerals Ltd.

MCMILLAN SHAKESPEARE ADR by McMillan Shakespeare Ltd

McMillan Shakespeare Ltd

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems Inc

Macarthur Minerals Ltd

MITSU MNG&SMLTNG UNSP/ADR by Mitsu Mining & Smelting Co., Ltd.

Mitsui Mining and Smelting Co Ltd

Mirrored Microsoft

WIIM

Maximus shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.

Maximus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) raises FY2025 Adj EPS guidance from $5.90-$6.20 to $6.30-$6.60 vs $6.10 analyst estimate. Raises FY2025 sales outlook from $5.20 billion-$5.35 billion to $5.25 billion-$5.40 billion vs $5.30 billion estimate.

News

Guidance

Maximus Raises FY2025 Adj EPS Guidance from $5.90-$6.20 to $6.30-$6.60 vs $6.10 Est; Raises FY2025 Sales Guidance from $5.20B-$5.35B to $5.25B-$5.40B vs $5.30B Est

Maximus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) reported quarterly earnings of $2.01 per share which beat the analyst consensus estimate of $1.38 by 45.65 percent. This is a 28.03 percent increase over earnings of $1.57 per share from the same period last year. The company reported quarterly sales of $1.36 billion which beat the analyst consensus estimate of $1.29 billion by 5.17 percent. This is a 0.96 percent increase over sales of $1.35 billion the same period last year.

Earnings

Earnings Beats

Maximus Q2 Adj. EPS $2.01 Beats $1.38 Estimate, Sales $1.36B Beat $1.29B Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Maximus shares are trading lower after the company reported Q1 financial results and cut its FY25 revenue guidance below estimates.

Maximus Raises FY25 Adj EPS Outlook From $5.70 - $6.00 To $5.90 - $6.20 Vs. $4.76 Est.

Maximus Trims FY25 Revenue Guidance From $5.275B - $5.425B To $5.2B - $5.35B Vs. $5.95B Est.

Maximus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) reported quarterly adjusted earnings of $1.61 per share which beat the analyst consensus estimate of $1.06 by 51.89 percent. This is a 20.15 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $1.40 billion which beat the analyst consensus estimate of $1.29 billion by 8.80 percent. This is a 5.65 percent increase over sales of $1.33 billion the same period last year.

Maximus Q1 Adj $1.61 Beats $1.06 Estimate, Sales $1.40B Beat $1.29B Estimate

AAMI

AGCO

AMRK

AMZN

APTV

CIGI

CRNC

DOCS

EMBC

ENTG

EXPE

EXPO

FARM

FBIN

FTNT

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

ILMN

INTR

KVUE

LADR

LESL

Laboratory Corporation Of America Holdings

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MPWR

MSGE

MTSI

Earnings Scheduled For February 6, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Gabriela Borges upgraded the rating for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Sell to Buy and raised the price target from $77 to $140. Cloudflare shares closed at $107.68 on Tuesday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James analyst Brian Gesuale upgraded Maximus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) from Market Perform to Outperform and announced a $90 price target. Maximus shares closed at $74.65 on Tuesday. <a href="https://www.benzinga.com/quote/MMS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Winter upgraded U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Neutral to Buy and increased the price target from $58 to $60. U.S. Bancorp shares closed at $47.83 on Tuesday. <a href="https://www.benzinga.com/quote/USB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Vijay Kumar upgraded the rating for Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) from In-Line to Outperform and raised the price target from $1375 to $1450. Mettler-Toledo Intl shares closed at $1,223.68 on Tuesday. <a href="https://www.benzinga.com/quote/MTD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Nicholas Campanella upgraded Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) from Equal-Weight to Overweight but lowered the price target from $91 to $84. Edison Intl shares closed at $79.84 on Friday. <a href="https://www.benzinga.com/quote/EIX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NET stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-1024x590.png" alt="" class="wp-image-715066" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02080622/image-6.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42740135/how-to-earn-500-a-month-from-alphabet-stock">How To Earn $500 A Month From Alphabet Stock</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

This Cloudflare Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Raymond James analyst Brian Gesuale upgrades Maximus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) from Market Perform to Outperform and announces $90 price target.

Price Target

Raymond James Upgrades Maximus to Outperform, Announces $90 Price Target

Buybacks

Maximus Board Authorizes $200M Increase Common Stock Purchase Program

On December 5, a recent SEC filing unveiled that Michelle Link, Chief Human Resources at Maximus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) made an insider sell.
What Happened: Link's recent move involves selling 2,208 shares of Maximus. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001032220/000095017024133496//Archives/edgar/data/1032220/000095017024133496/0000950170-24-133496-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value is $163,016.
As of Thursday morning, Maximus shares are down by 0.0%, currently priced at $74.66.
<h3>About Maximus</h3>
Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
<h3>Financial Insights: Maximus</h3>
Revenue Growth: Over the 3 months period, Maximus showcased positive performance, achieving a revenue growth rate of 4.44% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 22.93%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Maximus's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.2.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.69.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: Maximus's P/E ratio of 14.96 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.87, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 9.05 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001032220">Check Out The Full List Of Maximus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Sell Alert: Michelle Link Cashes Out $163K In Maximus Stock

Maximus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) shares are<a href="https://www.benzinga.com/general/health-care/24/11/42203859/maximus-stock-bounces-around-after-hours-tuesday-whats-going-on" target="_blank" rel="noreferrer noopener"> trading higher on Wednesday.</a>
Today, the company announced that the U.S. Department of Health and Human Services, Centers for Medicare &amp; Medicaid Services (CMS) has withdrawn their early re-procurement of the Contact Center Operations (CCO) 1-800-MEDICARE <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42205421/maximus-will-continue-to-perform-contact-center-operations-contract" rel="noreferrer noopener">and Federal Marketplace contract</a>.
The early re-procurement of the contract would have otherwise caused Maximus to recompete for the same scope of work it currently performs under its contract today, the company said.
The current contract retains its available option periods until 2031.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42211820/whats-going-on-with-teslas-chinese-rival-nio-stock-today" rel="noreferrer noopener">What&#8217;s Going On With Tesla&#8217;s Chinese Rival NIO Stock Today?</a>
&#8220;We are pleased with this outcome and appreciate the opportunity to continue supporting HHS and CMS in their vital missions and look forward to delivering innovative, high-quality, and reliable solutions that benefit the American public,&#8221; said Bruce Caswell, president and CEO of Maximus.
&#8220;Maximus employees have consistently demonstrated their ability to successfully manage this critical program providing essential support to more than 75 million eligible Americans who rely on Medicare and the Federal Marketplace,&#8221; Caswell said.
For FY25, Maximus sees revenues between $5.275 billion and $5.425 billion<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42099110/maximus-reports-fourth-quarter-and-full-year-results-for-fiscal-year-2024" rel="noreferrer noopener"> (estimate: $5.297 billion)</a>. Adjusted diluted earnings per share, which excludes expense for amortization of intangible assets and divestiture-related charges, is expected to range between $5.70 and $6.00 per share (estimate: $5.07).
Price Action: MMS shares were up 0.5% to $73.34 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says" target="_blank" rel="noreferrer noopener">‘It&#8217;s The Most Wonderful Time Of The Year&#8217; For The Stock Market, History Says</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Health Care

General

Maximus Secures Medicare Contract Through 2031, Shares Gain Momentum

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmaximus.com%2F&amp;esheet=54158762&amp;newsitemid=20241126626604&amp;lan=en-US&amp;anchor=Maximus&amp;index=1&amp;md5=26f28e5ecebffe14bcf89e1d5a14ed8b">Maximus</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) is pleased to announce that the U.S. Department of Health and Human Services, Centers for Medicare &amp; Medicaid Services (CMS) has withdrawn their early re-procurement of the Contact Center Operations (CCO) 1-800-MEDICARE and Federal Marketplace contract. The early re-procurement of the contract would have otherwise caused Maximus to recompete for the same scope of work it currently performs under its contract today. The current contract retains its available option periods until 2031.

Reported Earlier, Maximus Retains Key CMS Contract, Securing Contact Center Operations Through 2031

Maximus Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) shares are volatile in extended trading Tuesday after the company announced the cancellation of a <a href="https://www.benzinga.com/pressreleases/24/11/b42201228/u-s-department-of-health-and-human-services-centers-for-medicare-and-medicaid-services-notify-maxi">contact center operations contract</a>.
What Happened: After the market close on Tuesday, Maximus said it received notification from the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS) that the federal agency has canceled the Contact Center Operations (CCO) 1-800-MEDICARE and Federal Marketplace solicitation.
The company said the contract covered the same scope of work Maximus currently performs under separate contracts through option periods available until 2031.
&#8220;Maximus employees have consistently demonstrated their ability to successfully manage this critical program providing essential support to more than 75 million eligible Americans who rely on Medicare and the Federal Marketplace,&#8221; said Bruce Caswell, president and CEO of Maximus.
&#8220;We appreciate the opportunity to continue supporting HHS and CMS in their vital missions and look forward to delivering innovative, high-quality, and reliable solutions that benefit the American public.&#8221;
Maximus helps improve the delivery of public services&nbsp;as a strategic partner to governments around the world.
MMS Price Action: Maximus shares were volatile at the start of the after-hours session, but were trading approximately flat by the time of publication Tuesday at $73, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42202858/workday-stock-slides-after-q3-results-beat-expectations-fy-subscription-revenue-guidance-revised-lower">Workday Stock Slides After Q3 Results Beat Expectations, FY Subscription Revenue Guidance Revised Lower</a></li>
</ul>
Photo: Shutterstock.

Government

After-Hours Center

Movers

Maximus Stock Bounces Around After Hours Tuesday: What's Going On?

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmaximus.com&amp;esheet=54158662&amp;newsitemid=20241126053073&amp;lan=en-US&amp;anchor=Maximus&amp;index=1&amp;md5=a7d9f87c1b7dd3fbe9a85187dc328bbe">Maximus</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>), a leading employer and provider of government services worldwide, announced the U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services (CMS) notified Maximus they have cancelled the Contact Center Operations (CCO) 1-800-MEDICARE and Federal Marketplace solicitation which covered the same scope of work Maximus currently performs under contract today through option periods available until 2031.

Biotech

U.S. Department Of Health And Human Services, Centers For Medicare And Medicaid Services Notify Maximus Of Cancellation Of The Contact Center Operations Contract Re-Procurement

Maximus Shares Halted On Circuit Breaker To The Downside, Stock Now Down -0.77%

Maximus shares are trading lower after the company on Wednesday reported worse-than-expected Q4 adjusted EPS results.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Thursday.
Shares of Maximus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/MMS/earnings">worse-than-expected fourth-quarter adjusted EPS results.</a>
Maximus reported quarterly earnings of $1.46 per share which missed the analyst consensus estimate of $1.50 per share. The company reported quarterly sales of $1.32 billion which beat the analyst consensus estimate of $1.31 billion.
Maximus shares dipped 4.4% to $76.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) shares declined 16.7% to $13.25 in pre-market trading. Kura Oncology and Kyowa Kirin announced a global strategic collaboration to develop and commercialize Ziftomenib in Acute Leukemias.</li>
<li>Atkore Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NASDAQ">ATKR</a>) shares dipped 9.7% to $76.00 in pre-market trading after the company reported downbeat fourth-quarter earnings.</li>
<li>Cool Company Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLCO#NASDAQ">CLCO</a>) fell 9.7% to $9.59 in pre-market trading after the company announced third-quarter results.</li>
<li>Centessa Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) fell 9.7% to $15.10 in today's pre-market trading.</li>
<li>Xponential Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) fell 8.7% to $14.01 in pre-market trading.</li>
<li>PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) fell 7.1% to $108.20 in pre-market trading following weak quarterly results.</li>
<li>Scholastic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) fell 2.4% to $24.21 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42103475/nvidia-deere-and-3-stocks-to-watch-heading-into-thursday">Nvidia, Deere And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

ATKR

CLCO

CNTA

KURA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SCHL

XPOF

Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Press Releases

Maximus Will Continue to Perform Contact Center Operations Contract

Maximus Completes Divestiture of Australia and South Korea in Outside the U.S. Segment

Comments

Maximus

Maximus (MMS) Options

Maximus (NYSE:MMS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL